From 20 10 to 10, based on the comprehensive consideration of corporate culture construction in four aspects: organization advocacy, guarantee mechanism, atmosphere creation and business performance, Consistent Pharmaceutical won the title of national pharmaceutical enterprise culture construction demonstration unit on 20 10, becoming one of the 22 award-winning pharmaceutical enterprises in China.
On 20 10, 10, Unipharma successfully delisted from the Beijing Equity Exchange, and signed an equity transfer agreement with China Pharmaceutical Group Company, formally acquiring 52.6 1% equity of Sinopharm Shenzhen Traditional Chinese Medicine Co., Ltd., and Shenzhen Traditional Chinese Medicine returned to the Unipharma family and became a wholly-owned subsidiary of Unipharma.
20 10 September, Shenzhen Municipal People's Government and China Pharmaceutical Group Company signed a strategic cooperation framework agreement in Wuzhou Hotel. As an enterprise of China Pharmaceutical Group in Shenzhen, Unipharma will seize the opportunity, actively participate in the development of emerging industries in Shenzhen, strengthen cooperation, and create a successful example of win-win cooperation and common development between central enterprises and local governments.
20 10 September, the signing ceremony of the acquisition of Huizhou Zhongsheng Pharmaceutical Co., Ltd. by Consistent Pharmaceutical was held in Guangzhou. This acquisition is another powerful measure for Consistent Pharmaceutical to implement the strategy of extension expansion and further implement the strategy of network sinking.
20 10 September, the 3rd China Best Board Award Reception and the 20 10 China Board Value Management Forum were held in Shenzhen. Consistent Pharmaceutical won two awards, "Top 50 Best Board of Directors of Main Board Listed Companies in China in 20 10" and "Top 50 Best Board of Directors of Listed Companies in China in 20 10", which showed that the capital market and industry authorities recognized Consistent Pharmaceutical's strengthening of corporate governance and attaching importance to the strategic decision-making role of the board of directors.
On August 20 10, Consistent Pharmaceutical was awarded the license by Guangdong Price Bureau "Member Unit of Guangdong Price Index Platform", and the standardized drug price management of the company was recognized by government departments.
On August 20 10, the 20 10 national pharmaceutical industry information annual meeting and the first national pharmaceutical top 100 enterprise conference were held in Shanghai, and Youli Pharmaceutical won the title of "Top 100 Pharmaceutical Industry in China".
On July 20 10, Unipharma Shenzhen Modern Logistics Center was relocated and expanded. The new logistics center adopts the world-leading Manhattan warehousing and distribution management system and international standard modern warehousing management facilities and equipment, and the automation level and throughput are greatly improved.
On June 20 10, the signing ceremony of merger and acquisition of Meizhou Xinte Pharmaceutical Co., Ltd. was held in Guangzhou, opening a new chapter in the eastern Guangdong market.
20 10 in may, the high-end seminar on the fifth anniversary of Shenzhen Stock Exchange Index and the first prize-giving ceremony for high-quality listed companies of Shenzhen Stock Exchange Index were held in Shenzhen. Consistent Pharmaceutical won four awards: Excellent Listed Company of Shenzhen Stock Exchange Index, Industry Leading Award of Shenzhen Stock Exchange Index, Best Brand Marketing Listed Company of Shenzhen Stock Exchange Index and Most Socially Responsible Listed Company of Shenzhen Stock Exchange Index.
On April 20 10, the signing ceremony of the reorganization of Shenzhen yanfeng pharmaceutical co., ltd was held in Shenzhen, which marked another important step in the integration of distribution business of youli pharmaceutical. The two sides will complement each other and jointly expand the distribution market in Shenzhen.
On April 20 10, Sinopharm Holdings Zhanjiang Co., Ltd. went public. State-controlled Zhanjiang Company will rely on the integrated operation platform, give full play to the advantages of localization, devote itself to the drug distribution business in western Guangdong, and strive to become a pioneer in regional market development.
20 10 February, Sinopharm Holdings Nanning Co., Ltd. acquired the pharmaceutical business of Nanning Pharmaceutical Co., Ltd., which consolidated the dominant position of Unipharm in Guangxi and further enhanced its brand influence.
On October 20 10 1 month, Guangdong Consistent Hengxing Pharmaceutical Co., Ltd. celebrated its relocation. The successful establishment and formal operation of Consistent Hengxing shoulders the important mission of consistent pharmaceutical distribution network sinking. June 5438+February 2009, Sinopharm Holdings Zhanjiang Co., Ltd. was established. On the one hand, it ensures the position of Consistent Pharmaceutical in Zhanjiang Hospital sales market; At the same time, it brings integration value to customer resource optimization, product line enrichment and customer satisfaction improvement.
In July, 2009, in the first top 20 listed pharmaceutical companies in China and the selection of listed pharmaceutical companies with the most investment value in 2009 10, Consistent Pharmaceutical won the title of "Top 20 Most Competitive Pharmaceutical Listed Companies in China".
In June 2009, the equity acquisition of Sinopharm Nanning Co., Ltd. was completed, and the competitiveness of Sinopharm South China distribution market was improved.
In March 2009, Dongguan Consistent Medicine Co., Ltd. was established. Consistent pharmaceutical has taken another solid step in implementing the strategy of sinking distribution network and distributing market layout in Guangdong Province.
In February, 2009, Unipharma invested 1 100 million yuan to acquire 75% equity of Suzhou Wanqing Pharmaceutical Co., Ltd., which started the prelude of industry consolidation and laid a good foundation for achieving the goal of "making China cephalosporin with the most complete standards and China cephalosporin with the best quality".
In February 2009, Guangzhou Logistics Center with an investment of 65.438+0.4 billion yuan officially opened, becoming the first enterprise in South China to be approved for third-party medical logistics. A stepped distribution network of Guangdong and Guangxi with Guangzhou Logistics Center as the core has taken shape. In June 2008, Sinopharm Holdings Foshan Co., Ltd. was established, which became an important measure to enlarge, deepen and refine the distribution network, implement network sinking, lay out the Guangdong market and build terminal control.
From June 5438 to October 2008 10, with its unique management and cultural innovation and good economic and social benefits achieved over the years, Consistent Pharmaceutical won the Guangdong Pharmaceutical Industry Innovation Enterprise Award and the Guangdong Pharmaceutical Industry Outstanding Contribution Enterprise Award for 30 years of reform and opening up.
In August, 2008, Sinopharm Holdings Guangzhou Co., Ltd., the core enterprise of drug distribution of Sinopharm Group, and Wyeth (China) formally signed the sales agreement of "Peier" -7-valent pneumococcal capsular polysaccharide conjugate vaccine in South China, and the blockbuster "Peier" vaccine in medical field officially landed in China.
In April, 2008, Uniqlo Medicine Jianmin Branch was officially renamed as Shenzhen Jianmin Medicine Co., Ltd., and operated as a second-level legal entity of Uniqlo Medicine. It is an important measure to consolidate Shenzhen's position in the distribution market and maintain its sustainable competitiveness.
In March, 2008, Shenzhen Zhijun Pharmaceutical Co., Ltd., a subsidiary of Unipharma, signed an exclusive license agreement with South Korea's Liu Han Foreign Firm * *, and entered the field of digestive system drugs from a high starting point. In March 2007, Guangdong Consistent Pharmacy Co., Ltd. was established, forming an integrated operation system of cross-regional retail chains.
In February 2006, 65438 Xiehe Pharmaceutical R&D and its manufacturing base with a total investment of 228 million yuan and an area of 45,000 square meters were completed and put into operation.
In June 2006, Shenzhen Pharmaceutical Factory was renamed as Shenzhen Zhijun Pharmaceutical Co., Ltd., and the brand strategy of the pharmaceutical industry entered a new stage.
In April 2006, the share-trading reform was completed.
In April 2006, we started a comprehensive resource integration and implemented the integration strategy.
On June 5438+ 10, 2006, it acquired 90% equity of Sinopharm Holding Guangzhou Co., Ltd., forming a distribution network layout in southern China with Sinopharm Holding Guangzhou Co., Ltd. as the core enterprise.
From June, 5438 to February, 2004, Sinopharm Holdings Co., Ltd. entered Shenzhen Consistent Pharmaceutical Co., Ltd., with 43.33% equity, becoming the largest shareholder of Consistent Pharmaceutical.
From June, 5438 to February, 2000, it was restructured by Shenzhen Municipal Government, replaced and listed, and changed its name to Shenzhen Consistent Pharmaceutical Co., Ltd.
1985 in may, the company's predecessor, Shenzhen pharmaceutical production and supply corporation, was established.